GEN Exclusives

More »

GEN Poll

More »
May 22, 2012

FDA Performance

Four recently released reports paint a decidedly mixed picture of FDA’s ability to bring drugs and biologics to market. California Healthcare Institute (CHI) and The Boston Consulting Group (BCG) fault FDA’s accelerated approval processes for favoring AIDS and cancer over diseases like diabetes, obesity, and heart disease. A Manhattan Institute report blames lack of development in these areas on the sky-high cost of Phase III trials, especially for heart-disease drugs. But a paper in NEJM suggests that FDA outstrips its European and Canadian counterparts in most areas of performance. And GAO concluded the agency met most of its performance goals between FY 2000 and FY 2010.

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

A Lot
 
  13.3%
Some
 
  30.0%
Not Much
 
  56.7%
Undecided
 
  0.0%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?